Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tomoyuki Harada.
Critical Care | 2012
Arino Yaguchi; Junji Yuzawa; David J. Klein; Munekasu Takeda; Tomoyuki Harada
IntroductionThe Endotoxin Activity Assay (EAA) is a useful test to risk stratify patients with severe sepsis and assess for Gram negative infection. However, the significance of intermediate levels of EAA (0.4-0.59) at the bedside has not been well elucidated. The purpose of this study was to interpret intermediate EAA levels in clinical practice.MethodsThis retrospective observational study included all adult patients with suspected sepsis admitted to our medico-surgical intensive care unit (ICU) in whom EAA was measured from July 2008 to September 2011. Data collected included EAA, white blood cell (WBC) count and differential, C-reactive protein (CRP), procalcitonin (PCT) and bacterial cultures. Data were analyzed by comparative statistics.ResultsTwo hundred and ten patients were studied. Ninety two (43%) patients had culture documented gram negative infection. Patients with Gram-negative organisms in cultures had significantly higher EAA levels (0.47, IQR 0.27) than those without any Gram-negative organisms in cultures (0.34, IQR 0.22) (p < 0.0001). For patients with intermediate EAA levels (0.40 to 0.59), PCT levels and presence of left shift of WBC significantly differed between patients with Gram negative organisms in their blood or other cultures and those who had no organisms in any of the cultures (4.9 versus 1.7 ng/mL, p < 0.05; 57.9 versus 18.9%, p < 0.0004, respectively).ConclusionsWe confirm that high levels of EAA in our cohort of patients with suspected sepsis are strongly associated with gram negative infection. In those patients with intermediate elevation in EAA levels, use of PCT and WBC differential can provide additional diagnostic value to clinicians at the bedside.
Critical Care | 2012
Arino Yaguchi; Mari Yokota; Taijiro Goto; Munekazu Takeda; R Moroi; Tomoyuki Harada; Mizuho Namiki
Critical Care | 2014
M Tsunoda; M Kang; M Saito; Noriko Saito; Mizuho Namiki; Tomoyuki Harada; Munekazu Takeda; Arino Yaguchi
Critical Care | 2014
M Kang; M Tsunoda; M Saito; Noriko Saito; Mizuho Namiki; Munekazu Takeda; Tomoyuki Harada; Arino Yaguchi
Critical Care | 2014
K Mocjiduki; H Suzuki; A Kawasaki; M Hotta; Mizuho Namiki; Tomoyuki Harada; Munekazu Takeda; Arino Yaguchi
Journal of Clinical Toxicology | 2013
Syuji Shimamoto; Mizuho Namiki; Tomoyuki Harada
Critical Care | 2013
Noriko Saito; Mari Yokota; Ahmin Kim; Tomoyuki Harada; Munekazu Takeda; Mizuho Namiki; Arino Yaguchi
Critical Care | 2013
Mari Yokota; Ahmin Kim; Taijiro Goto; Tomoyuki Harada; Munekazu Takeda; Mizuho Namiki; Arino Yaguchi
Critical Care | 2013
Noriko Saito; Munekazu Takeda; Tomoyuki Harada; R Moroi; Mizuho Namiki; Arino Yaguchi
Critical Care | 2013
Ahmin Kim; Mari Yokota; Noriko Saito; Munekazu Takeda; Tomoyuki Harada; Mizuho Namiki; Arino Yaguchi